Is EINECS 254-905-2 Safe in Breastfeeding

I am a breastfeeding mother and i want to know if it is safe to use EINECS 254-905-2? Is EINECS 254-905-2 safe for nursing mother and child? Does EINECS 254-905-2 extracts into breast milk? Does EINECS 254-905-2 has any long term or short term side effects on infants? Can EINECS 254-905-2 influence milk supply or can EINECS 254-905-2 decrease milk supply in lactating mothers?

It is composed by bisphosphonates Most bisphosphonates are acidic compounds that achieve low plasma concentration. Both features make it unlikely excretion into the milk in clinically significant amount. Intestinal absorption of bisphosphonates is very low even during fasting and is considered negligible in the presence of milk due to formation with the calcium of non absorbable compounds. EINECS 254-905-2 is excreted into breast milk in clinically insignificant amount and no problems have been observed in infants whose mothers were treated, except some cases of mild and asymptomatic hypocalcemia in infants whose mothers had been already treated before and / or during pregnancy, so some authors suggest regular monitoring of serum calcium.

Limited information indicates that maternal doses of EINECS 254-905-2 of 30 mg intravenously produce very low levels in milk. Because EINECS 254-905-2 has a serum half-life of about 3 hours, is highly bound to calcium and is poorly absorbed orally (0.3 to 3% in adults), absorption of EINECS 254-905-2 by a breastfed infant is unlikely.[1] Until more data become available, withholding nursing for 12 to 24 hours after a dose should ensure that the breastfed infant is exposed to little or no EINECS 254-905-2. Other evidence indicates that breastfeeding after cessation of long-term EINECS 254-905-2 treatment appears to have no adverse effects on the infant. Some experts recommend monitoring the infant's serum calcium during the first 2 months postpartum if the mother received EINECS 254-905-2 during pregnancy or nursing.[2]

A mother received intravenous EINECS 254-905-2 30 mg once monthly beginning 6 months postpartum. She pumped her breasts and discarded the milk for 48 hours after each dose. The infant, who was about 80% breastfed throughout maternal EINECS 254-905-2 therapy, remained healthy and grew normally during this time.[1] Because EINECS 254-905-2 can persist in the body for years after long-term administration, the following cases may be relevant. Three women received EINECS 254-905-2 intravenously for osteogenesis imperfecta or McCune-Albright syndrome in cumulative dosages of 6, 7.5 and 9 mg/kg annually for 2 years, 4 years, and 2.2 years, respectively. Their last doses were 3 months, 3 and 48 months (2 infants), and 21 months prior to conception, respectively. None of the women resumed EINECS 254-905-2 during breastfeeding, but they all breastfed their infants postpartum, one for 18 months, two for undetermined times, and one for 6 weeks. None of the infants had any evidence of adverse effects of EINECS 254-905-2.[3] Two other mothers received intravenous EINECS 254-905-2 infusions preconception and during pregnancy. On received a total of 240 mg with the final dose during the first trimester of pregnancy. She exclusively breastfed her infant for 6 months and continued breastfeeding until the infant was 12 months old. Her infant grew normally and had no adverse reactions.[4] Another woman received alendronate for 6 months, then EINECS 254-905-2 every 4 months for 1 year prior to conception. Her infant was breastfed (extent not stated) for 3 months. The infant had mild hypocalcemia at 2 months of age, but a normal calcium level and normal long bone development at 5 months of age.[5] A woman developed transient osteoporosis with foot pain during pregnancy. On days 3 and 8 postpartum and 2 months later, she received 30 mg of EINECS 254-905-2 intravenously. She was instructed to discard her breastmilk for 24 hours after each dose. Her breastfed (extent not stated) infant had normal growth and development at 15 months of age.[6]